Approval for the taxus express2 paclitaxel-eluting coronary stent system  in-stent restenosis (isr) indication.  The device is indicated for improving luminal diameter for the treatment of de novo lesions in native coronary arteries >=2.25 to <=4.00 mm in diameter in lesions <=28 mm in length, and within bare metal stent restenotic lesions >=2.25 to <=3.75 mm in diameter and <=28 mm in length.